Earkart Ltd: Q2 FY27 Revenue from Operations at Rs. 3,090.75 Lakh
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 05 Nov 2026, 03:32 PM IST · BSE ID: 5696a6b6-77b4-4942-bfe3-6c123fe82b0e
View Original BSE Filing (PDF)
💡
In Simple Terms
Earkart Limited released its half-year financial results, showing Rs. 3,108.81 Lakh total income and Rs. 116.68 Lakh profit.
🤖 AI Summary
- Earkart Limited reported total income of Rs. 3,108.81 Lakh for the half year ended September 30, 2026.
- Profit After Tax for the half year ended September 30, 2026, was Rs. 116.68 Lakh.
- Basic Earnings Per Share (EPS) for the half year stood at Rs. 0.85.
- The company incorporated two subsidiaries: Earkart Pharmaceuticals Private Limited and Earkart Health Limited (UK).
- Consolidated financial results for the period include these new subsidiary operations.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Half Year Ended Sep 30, 2026)
3,090.75 Lakh
38.68
Total income (Half Year Ended Sep 30, 2026)
3,108.81 Lakh
39.32
Profit After Tax (Half Year Ended Sep 30, 2026)
116.68 Lakh
-37.04
Basic Earnings per share (Half Year Ended Sep 30, 2026)
0.85 Rs
-37.04
Cash and Cash Equivalents (As at Sep 30, 2026)
227.86 Lakh
🏢 How This Affects the Company
The incorporation of two new subsidiaries, Earkart Pharmaceuticals Private Limited and Earkart Health Limited, indicates an expansion into new business segments or geographies.
The company reported a Profit After Tax of Rs. 116.68 Lakh for Q2 FY27. Cash and Cash Equivalents decreased to Rs. 227.86 Lakh as of September 30, 2026, from Rs. 2,168.67 Lakh as of March 31, 2026.
The new subsidiaries will likely introduce new operational structures and requirements for the company, integrating pharmaceutical and health sectors.
Expanding into new sectors and international markets (UK) through subsidiaries introduces new operational and regulatory risks associated with these industries and geographies.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the reported Profit After Tax of Rs. 116.68 Lakh and Basic EPS of Rs. 0.85 for the half year.
🔍
Management Signal
The management's decision to incorporate two new subsidiaries, Earkart Pharmaceuticals and Earkart Health, signals an intent for business diversification and expansion into healthcare sectors.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Q3 FY27 results — monitor profit after tax trend and cash position.
Updates on new subsidiaries — track their operational progress and financial contribution.
Balance sheet updates — observe changes in non-current investments and borrowings.
MEDIUM RISK
Decreased cash reserves and lower profit after tax, alongside new subsidiary integration, indicate elevated financial and operational risk.
💡 Investor Takeaway
Earkart Ltd reported a Profit After Tax of Rs. 116.68 Lakh for the half year ended September 30, 2026, a decrease from Rs. 185.33 Lakh in the prior comparable period. Revenue from operations grew to Rs. 3,090.75 Lakh. Cash and Cash Equivalents declined substantially to Rs. 227.86 Lakh.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from operations increased to Rs. 3,090.75 Lakh for Q2 FY27, up from Rs. 2,228.57 Lakh in Q2 FY26.
- Total Equity & Liabilities increased to Rs. 7,074.15 Lakh as of September 30, 2026, from Rs. 6,949.20 Lakh as of March 31, 2026.
⚠️ Concerns
- Profit After Tax decreased to Rs. 116.68 Lakh in Q2 FY27 from Rs. 185.33 Lakh in Q2 FY26.
- Cash and Cash Equivalents significantly decreased to Rs. 227.86 Lakh as of September 30, 2026, from Rs. 2,168.67 Lakh as of March 31, 2026.
📅 Company Track Record
Earkart Limited was incorporated in 2021 (CIN: L74999DL2021PLC399313). No prior filings with comparable financial data or significant events were found, indicating a relatively short public track record.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Earkart Ltd's total income for the half year ended September 30, 2026?
Earkart Limited reported a total income of Rs. 3,108.81 Lakh for the half year ended September 30, 2026, compared to Rs. 2,231.18 Lakh for the half year ended September 30, 2025.
What was Earkart Ltd's Profit After Tax for Q2 FY27?
The Profit After Tax for Earkart Limited for the half year ended September 30, 2026 (Q2 FY27) was Rs. 116.68 Lakh, down from Rs. 185.33 Lakh in the prior comparable period.
What is Earkart Ltd's Basic Earnings Per Share for the period ended September 30, 2026?
Earkart Limited's Basic Earnings Per Share for the half year ended September 30, 2026, was Rs. 0.85. This compares to Rs. 1.35 for the half year ended September 30, 2025.
Did Earkart Ltd incorporate any new subsidiaries during the half year ended September 30, 2026?
Yes, Earkart Limited incorporated two subsidiaries: Earkart Pharmaceuticals Private Limited (wholly owned, India) and Earkart Health Limited (65% equity, United Kingdom).
What were Earkart Ltd's Cash and Cash Equivalents as of September 30, 2026?
As of September 30, 2026, Earkart Limited's Cash and Cash Equivalents stood at Rs. 227.86 Lakh, a decrease from Rs. 2,168.67 Lakh as of March 31, 2026.
Questions based on this BSE filing only. For information purposes.